VISTAGEN THERAPEUTICS, INC. Revenue Not from Contract with Customer
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Revenue Not from Contract with Customer of $354.10 thousand for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RevenueNotFromContractWithCustomer · last filed 2021-08-12
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2021-06-30 was $354.10K.
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2021-03-31 was $442.00K.
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2020-12-31 was $314.00K.
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for the quarter ending 2020-09-30 was $334.00K.
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for fiscal 2021 was $1.09M.
- VISTAGEN THERAPEUTICS, INC. revenue not from contract with customer for fiscal 2020 was $0.00.
| Period end | Revenue Not from Contract with Customer 3 month | Revenue Not from Contract with Customer 6 month | Revenue Not from Contract with Customer 9 month | Revenue Not from Contract with Customer 12 month |
|---|---|---|---|---|
| 2021-06-30 | $354.10K 10-Q · filed 2021-08-12 | $796.10K derived: sum of 2 quarters · filed 2021-08-12 | $1.11M derived: sum of 3 quarters · filed 2021-08-12 | $1.44M derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | $442.00K 10-K · filed 2021-06-29 | $756.00K derived: sum of 2 quarters · filed 2021-06-29 | $1.09M derived: sum of 3 quarters · filed 2021-06-29 | $1.09M 10-K · filed 2021-06-29 |
| 2020-12-31 | $314.00K 10-K · filed 2021-06-29 | $648.00K derived: sum of 2 quarters · filed 2021-06-29 | $648.00K derived: sum of 3 quarters · filed 2021-08-12 | $648.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-09-30 | $334.00K 10-K · filed 2021-06-29 | $334.00K derived: sum of 2 quarters · filed 2021-08-12 | $334.00K derived: sum of 3 quarters · filed 2021-08-12 | $334.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 2 quarters · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-08-12 | $0.00 derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $0.00 10-K · filed 2021-06-29 | $0.00 derived: sum of 2 quarters · filed 2021-06-29 | $0.00 derived: sum of 3 quarters · filed 2021-06-29 | $0.00 10-K · filed 2021-06-29 |
| 2019-12-31 | $0.00 10-K · filed 2021-06-29 | $0.00 derived: sum of 2 quarters · filed 2021-06-29 | $0.00 derived: sum of 3 quarters · filed 2021-06-29 | |
| 2019-09-30 | $0.00 10-K · filed 2021-06-29 | $0.00 derived: sum of 2 quarters · filed 2021-06-29 | ||
| 2019-06-30 | $0.00 10-K · filed 2021-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |